These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 20225990

  • 1. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.
    Pillai L, Burnett BP, Levy RM, GOAL Study Cooperative Group.
    Curr Med Res Opin; 2010 May; 26(5):1055-63. PubMed ID: 20225990
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA.
    Walton SM, Schumock GT, McLain DA.
    Curr Med Res Opin; 2010 Sep; 26(9):2253-61. PubMed ID: 20690891
    [Abstract] [Full Text] [Related]

  • 4. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA, Derry S, Phillips CJ, McQuay HJ.
    BMC Musculoskelet Disord; 2006 Oct 20; 7():79. PubMed ID: 17054784
    [Abstract] [Full Text] [Related]

  • 5. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
    Sebaldt RJ, Petrie A, Goldsmith CH, Marentette MA.
    Am J Manag Care; 2004 Nov 20; 10(11 Pt 1):742-50. PubMed ID: 15623264
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S, Bjørke PA.
    Rheumatology (Oxford); 2002 Apr 20; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [Abstract] [Full Text] [Related]

  • 9. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, Griffin MR.
    Gastroenterology; 2007 Sep 20; 133(3):790-8. PubMed ID: 17854591
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D.
    J Rheumatol; 2002 Mar 20; 29(3):467-73. PubMed ID: 11908558
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience.
    Pareek A, Chandanwale AS, Oak J, Jain UK, Kapoor S.
    Curr Med Res Opin; 2006 May 20; 22(5):977-88. PubMed ID: 16709320
    [Abstract] [Full Text] [Related]

  • 15. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM, Hindley CE.
    Clin Ther; 2010 Apr 20; 32(4):667-77. PubMed ID: 20435236
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
    Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M, CAPSS-114 Study Group.
    J Rheumatol; 2004 Jan 20; 31(1):150-6. PubMed ID: 14705234
    [Abstract] [Full Text] [Related]

  • 17. Gender differences in NSAID use among older adults with osteoarthritis.
    Dominick KL, Ahern FM, Gold CH, Heller DA.
    Ann Pharmacother; 2003 Nov 20; 37(11):1566-71. PubMed ID: 14565813
    [Abstract] [Full Text] [Related]

  • 18. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
    Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT.
    Clin Gastroenterol Hepatol; 2006 Nov 20; 4(11):1337-45. PubMed ID: 17088110
    [Abstract] [Full Text] [Related]

  • 19. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Laine L.
    Rev Gastroenterol Disord; 2004 Nov 20; 4 Suppl 4():S33-41. PubMed ID: 15580145
    [Abstract] [Full Text] [Related]

  • 20. Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study.
    Arboleya LR, de la Figuera E, Soledad García M, Aragón B, VICOXX Study Group.
    Curr Med Res Opin; 2003 Nov 20; 19(4):288-97. PubMed ID: 12841921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.